AQR Capital Management
IMVT icon

AQR Capital Management’s Immunovant IMVT Stock Holding History

AQR Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,082
Closed -$287K – 2903
2024
Q3 		$287K Sell
10,082
-76,201
-88% -$2.25M ﹤0.01% 2411
2024
Q2 		$2.28M Sell
86,283
-2,315
-3% -$65.8K ﹤0.01% 1405
2024
Q1 		$2.86M Buy
88,598
+19,634
+28% +$716K ﹤0.01% 1242
2023
Q4 		$2.91M Buy
68,964
+43,270
+168% +$1.59M 0.01% 1182
2023
Q3 		$986K Sell
25,694
-34,532
-57% -$781K ﹤0.01% 1604
2023
Q2 		$1.14M Buy
60,226
+35,501
+144% +$662K ﹤0.01% 1498
2023
Q1 		$383K Buy
+24,725
New +$429K ﹤0.01% 1865

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Capital Management's IMVT Position: Q4 2024 in Review

AQR Capital Management sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 10,082 shares — an estimated $287K sold.

AQR Capital Management first reported a position in IMVT in Q1 2023 and held it in 7 quarters. The position peaked at $2.91M in Q4 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • AQR Capital Management reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • AQR Capital Management sold 10,082 Immunovant shares in Q4 2024, an estimated $287K.
  • AQR Capital Management first reported a position in Immunovant in Q1 2023 and held it in 7 quarters.
  • AQR Capital Management's Immunovant position peaked at $2.91M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on AQR Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.